EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta‐analysis

David C Chen iD, Siyu Huang iD, Nathan Papa iD, Shankar Siva iD, Damien M Bolton iD, Nathan Lawrentschuk iD, Louise Emmett, Declan G Murphy iD, Michael S Hofman iD, Marlon L Perera iD

BJU International · 2025-05 · 135 (5) · 720-732

DOI: 10.1111/bju.16608 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift BJU International, online erschienen am 07.01.2025. Verfasst von David C Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Antigens, Surface, Glutamate Carboxypeptidase II, Prostatectomy, Prostatic Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To perform a systematic review and meta‐analysis to assess the relationship between intraprostatic maximum standardised uptake value (SUV max ) of the dominant prostatic lesion as measured on preoperative prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) with radical prostatectomy International Society of Urological Pathology (ISUP) Grade Group, pathological tumour (pT) staging, and biochemical recurrence (BCR).

Methods

Prostate‐specific membrane antigen PET may offer non‐invasive assessment of histopathological and oncological outcomes before definitive treatment. SUV max of the dominant lesion has been explored as a prognostic biomarker. Following the Preferred Reporting Items for Systematic Reviews and Meta‐analyses guidelines, we performed reviews of digital libraries and databases and retrieved studies reporting SUV max quantified on PSMA PET computed tomography or magnetic resonance imaging and subsequent radical prostatectomy ISUP Grade Group, pT stage, and BCR. Quality assessment was performed using Quality Assessment of Diagnostic Accuracy Studies‐2 and Prediction model Risk of Bias Assessment tools. Random effects meta‐analysis and meta‐regression by ISUP Grade Group and pT2 vs pT3/4 stage was performed. This study was registered on the International Prospective Register of Systematic Reviews (PROSPERO: CRD42023408170). Evidence Synthesis After removing duplicates, 23 studies were included for review. Pooled SUV max (95% confidence interval [CI]) increased monotonically with advancing ISUP Grade Group, with ISUP 1: 5.8 (95% CI 3.9–7.7), through to ISUP 5: 17.3 (95% CI 13.1–21.5). For pT2 disease, pooled SUV max : 9.7 (95% CI 7.8–11.5) increasing to 13.8 (95% CI 10.9–16.7) for pT3/4 disease. Substantial inconsistency was noted ( I 2 >50%) for all subgroups. This was not attenuated by restricting analysis only to studies using [ 68 Ga]Ga‐PSMA‐11. Narrative synthesis of six papers reporting BCR showed increasing SUV max was associated with reduced time to BCR.

Conclusion

Preoperative intraprostatic PSMA SUV max increases monotonically with higher ISUP Grade Group and pathological tumour stage. Higher SUV max is associated with reduced BCR‐free survival. However, the use of single SUV max thresholds for clinical decision making is not recommended as variability between studies is high.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, SurfaceGlutamate Carboxypeptidase IIProstatectomyProstatic NeoplasmsHumansMaleNeoplasm StagingPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

dominant intraprostatic lesionmaximum standardised uptake valuepositron emission tomographyprostate‐specific membrane antigenradical prostatectomy

Substanzen

Antigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase II

Autor:innen und Institutionen

  • Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Urology, Austin Health, Melbourne, Victoria, Australia.
  • Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, Grattan Street University of Melbourne, Melbourne, Victoria, Australia.

ORCID-Profile: David C Chen, Siyu Huang, Nathan Papa, Shankar Siva, Damien M Bolton, Nathan Lawrentschuk, Declan G Murphy, Michael S Hofman, Marlon L Perera

Zitieren

APA

Chen, D. C., Huang, S., Papa, N., Siva, S., Bolton, D. M., Lawrentschuk, N., Emmett, L., Murphy, D. G., Hofman, M. S., & Perera, M. L. (2025). Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta‐analysis. BJU International, 135(5), 720-732. https://doi.org/10.1111/bju.16608

Vancouver

Chen DC, Huang S, Papa N, Siva S, Bolton DM, Lawrentschuk N, et al. Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta‐analysis. BJU International. 2025;135(5):720-732. doi:10.1111/bju.16608

BibTeX
@article{Chen2025,
  author = {Chen, David C and Huang, Siyu and Papa, Nathan and Siva, Shankar and Bolton, Damien M and Lawrentschuk, Nathan and Emmett, Louise and Murphy, Declan G and Hofman, Michael S and Perera, Marlon L},
  title = {Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta‐analysis},
  journal = {BJU International},
  year = {2025},
  volume = {135},
  number = {5},
  pages = {720--732},
  doi = {10.1111/bju.16608}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche